1
|
Alshabrawy AK, Cui Y, Sylvester C, Yang D, Petito ES, Barratt KR, Sawyer RK, Heatlie JK, Polara R, Sykes MJ, Atkins GJ, Hickey SM, Wiese MD, Stringer AM, Liu Z, Anderson PH. Therapeutic Potential of a Novel Vitamin D3 Oxime Analogue, VD1-6, with CYP24A1 Enzyme Inhibitory Activity and Negligible Vitamin D Receptor Binding. Biomolecules 2022; 12:biom12070960. [PMID: 35883516 PMCID: PMC9312876 DOI: 10.3390/biom12070960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2022] [Revised: 06/29/2022] [Accepted: 06/30/2022] [Indexed: 02/04/2023] Open
Abstract
The regulation of vitamin D3 actions in humans occurs mainly through the Cytochrome P450 24-hydroxylase (CYP24A1) enzyme activity. CYP24A1 hydroxylates both 25-hydroxycholecalciferol (25(OH)D3) and 1,25-dihydroxycholecalciferol (1,25(OH)2D3), which is the first step of vitamin D catabolism. An abnormal status of the upregulation of CYP24A1 occurs in many diseases, including chronic kidney disease (CKD). CYP24A1 upregulation in CKD and diminished activation of vitamin D3 contribute to secondary hyperparathyroidism (SHPT), progressive bone deterioration, and soft tissue and cardiovascular calcification. Previous studies have indicated that CYP24A1 inhibition may be an effective strategy to increase endogenous vitamin D activity and decrease SHPT. This study has designed and synthesized a novel C-24 O-methyloxime analogue of vitamin D3 (VD1-6) to have specific CYP24A1 inhibitory properties. VD1-6 did not bind to the vitamin D receptor (VDR) in concentrations up to 10−7 M, assessed by a VDR binding assay. The absence of VDR binding by VD1-6 was confirmed in human embryonic kidney HEK293T cultures through the lack of CYP24A1 induction. However, in silico docking experiments demonstrated that VD1-6 was predicted to have superior binding to CYP24A1, when compared to that of 1,25(OH)2D3. The inhibition of CYP24A1 by VD1-6 was also evident by the synergistic potentiation of 1,25(OH)2D3-mediated transcription and reduced 1,25(OH)2D3 catabolism over 24 h. A further indication of CYP24A1 inhibition by VD1-6 was the reduced accumulation of the 24,25(OH)D3 , the first metabolite of 25(OH)D catabolism by CYP24A1. Our findings suggest the potent CYP24A1 inhibitory properties of VD1-6 and its potential for testing as an alternative therapeutic candidate for treating SHPT.
Collapse
Affiliation(s)
- Ali K. Alshabrawy
- UniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, SA 5001, Australia; (A.K.A.); (C.S.); (E.S.P.); (K.R.B.); (R.K.S.); (J.K.H.); (R.P.); (M.J.S.); (S.M.H.); (M.D.W.); (A.M.S.)
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Helwan University, Cairo 11795, Egypt
| | - Yingjie Cui
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China; (Y.C.); (Z.L.)
- Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China
| | - Cyan Sylvester
- UniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, SA 5001, Australia; (A.K.A.); (C.S.); (E.S.P.); (K.R.B.); (R.K.S.); (J.K.H.); (R.P.); (M.J.S.); (S.M.H.); (M.D.W.); (A.M.S.)
| | - Dongqing Yang
- Centre for Orthopaedic and Trauma Research, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA 5005, Australia; (D.Y.); (G.J.A.)
| | - Emilio S. Petito
- UniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, SA 5001, Australia; (A.K.A.); (C.S.); (E.S.P.); (K.R.B.); (R.K.S.); (J.K.H.); (R.P.); (M.J.S.); (S.M.H.); (M.D.W.); (A.M.S.)
| | - Kate R. Barratt
- UniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, SA 5001, Australia; (A.K.A.); (C.S.); (E.S.P.); (K.R.B.); (R.K.S.); (J.K.H.); (R.P.); (M.J.S.); (S.M.H.); (M.D.W.); (A.M.S.)
| | - Rebecca K. Sawyer
- UniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, SA 5001, Australia; (A.K.A.); (C.S.); (E.S.P.); (K.R.B.); (R.K.S.); (J.K.H.); (R.P.); (M.J.S.); (S.M.H.); (M.D.W.); (A.M.S.)
| | - Jessica K. Heatlie
- UniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, SA 5001, Australia; (A.K.A.); (C.S.); (E.S.P.); (K.R.B.); (R.K.S.); (J.K.H.); (R.P.); (M.J.S.); (S.M.H.); (M.D.W.); (A.M.S.)
| | - Ruhi Polara
- UniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, SA 5001, Australia; (A.K.A.); (C.S.); (E.S.P.); (K.R.B.); (R.K.S.); (J.K.H.); (R.P.); (M.J.S.); (S.M.H.); (M.D.W.); (A.M.S.)
| | - Matthew J. Sykes
- UniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, SA 5001, Australia; (A.K.A.); (C.S.); (E.S.P.); (K.R.B.); (R.K.S.); (J.K.H.); (R.P.); (M.J.S.); (S.M.H.); (M.D.W.); (A.M.S.)
| | - Gerald J. Atkins
- Centre for Orthopaedic and Trauma Research, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA 5005, Australia; (D.Y.); (G.J.A.)
| | - Shane M. Hickey
- UniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, SA 5001, Australia; (A.K.A.); (C.S.); (E.S.P.); (K.R.B.); (R.K.S.); (J.K.H.); (R.P.); (M.J.S.); (S.M.H.); (M.D.W.); (A.M.S.)
| | - Michael D. Wiese
- UniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, SA 5001, Australia; (A.K.A.); (C.S.); (E.S.P.); (K.R.B.); (R.K.S.); (J.K.H.); (R.P.); (M.J.S.); (S.M.H.); (M.D.W.); (A.M.S.)
| | - Andrea M. Stringer
- UniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, SA 5001, Australia; (A.K.A.); (C.S.); (E.S.P.); (K.R.B.); (R.K.S.); (J.K.H.); (R.P.); (M.J.S.); (S.M.H.); (M.D.W.); (A.M.S.)
| | - Zhaopeng Liu
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China; (Y.C.); (Z.L.)
| | - Paul H. Anderson
- UniSA Clinical and Health Sciences, Health and Biomedical Innovation, University of South Australia, Adelaide, SA 5001, Australia; (A.K.A.); (C.S.); (E.S.P.); (K.R.B.); (R.K.S.); (J.K.H.); (R.P.); (M.J.S.); (S.M.H.); (M.D.W.); (A.M.S.)
- Correspondence:
| |
Collapse
|
2
|
Li H, Fang Z, Dai H, Zhang H, Liu Y. Efficient Synthesis of Novel Oxime Analogues of the Hormone 1α, 25-Dihydroxyvitamin D3. JOURNAL OF CHEMICAL RESEARCH 2015. [DOI: 10.3184/174751915x14352521285949] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Calcitriol analogues which contained an oxime in the side chain were synthesised in five steps from an intermediate 22-nor Ketone. The key intermediate enones were synthesised by the Wittig–Horner olefination and Wittig olefination respectively. Reduction, oximation, photoisomerisation and deprotection gave the target compounds with the oxime at C-24.
Collapse
Affiliation(s)
- Hongliang Li
- School of Chemical Engineering, Nanjing University of Science &Technology, Nanjing 210094, P.R. China
| | - Zhijie Fang
- School of Chemical Engineering, Nanjing University of Science &Technology, Nanjing 210094, P.R. China
| | - Huanran Dai
- School of Chemical Engineering, Nanjing University of Science &Technology, Nanjing 210094, P.R. China
| | - Hengrui Zhang
- School of Chemical Engineering, Nanjing University of Science &Technology, Nanjing 210094, P.R. China
| | - Yanan Liu
- School of Chemical Engineering, Nanjing University of Science &Technology, Nanjing 210094, P.R. China
| |
Collapse
|
5
|
Sundaram S, Beckman MJ, Bajwa A, Wei J, Smith KM, Posner GH, Gewirtz DA. QW-1624F2-2, a synthetic analogue of 1,25-dihydroxyvitamin D3, enhances the response to other deltanoids and suppresses the invasiveness of human metastatic breast tumor cells. Mol Cancer Ther 2007; 5:2806-14. [PMID: 17121927 DOI: 10.1158/1535-7163.mct-06-0092] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The enzyme 24-hydroxylase, also known as CYP24, metabolizes 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] and is an established marker of vitamin D activity. Our studies evaluated the influence of a low-calcemic 1,25(OH)(2)D(3) analogue, QW-1624F2-2 (QW), on the regulation of CYP24 expression in MKL-4 cells, a metastatic mammary tumor cell model. 1,25(OH)(2)D(3) and its analogue, EB 1089, stimulated CYP24 induction at both protein and transcript levels. In contrast, QW failed to produce a sustained stimulation of CYP24, due, in large part, to a reduction in the stability of the CYP24 message. QW enhanced the capacity of 1,25(OH)(2)D(3) and EB 1089 to inhibit tumor cell proliferation by approximately 2-fold. QW also blocked the sustained induction of CYP24 expression by 1,25(OH)(2)D(3) and EB 1089, increased the potency of 1,25(OH)(2)D(3) and EB 1089, and inhibited breast tumor cell proliferation and invasion.
Collapse
Affiliation(s)
- Sujatha Sundaram
- Department of Surgery, Dartmouth Medical School, One Medical Center Drive, HB 7850, Lebanon, NH 03756, USA.
| | | | | | | | | | | | | |
Collapse
|
6
|
Posner GH, Kim HJ, Kahraman M, Jeon HB, Suh BC, Li H, Dolan P, Kensler TW. Highly antiproliferative, low-calcemic, side-chain ketone analogs of the hormone 1α,25-dihydroxyvitamin D3. Bioorg Med Chem 2005; 13:5569-80. [PMID: 16039132 DOI: 10.1016/j.bmc.2005.06.031] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2005] [Revised: 06/17/2005] [Accepted: 06/17/2005] [Indexed: 11/20/2022]
Abstract
A series 2a-4b of seven new side-chain ketone analogs of calcitriol (1) have been prepared. Unexpectedly, several of these 24- and 25-tert-butyl ketones, even though lacking the classical side-chain tertiary hydroxyl group, are considerably more antiproliferative in vitro than the hormone calcitriol (1) even at physiologically relevant low nanomolar concentrations and are less calcemic than calcitriol (1) in vivo. In addition, ketone analog 19-nor-2a is not significantly less calcemic in vivo than 19-methylene analog 2a.
Collapse
Affiliation(s)
- Gary H Posner
- Department of Chemistry, The Johns Hopkins University, Baltimore, MD 21218, USA.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Posner GH, Lee SHT, Kim HJ, Peleg S, Dolan P, Kensler TW. Novel A-ring analogs of the hormone 1α,25-dihydroxyvitamin D3: synthesis and preliminary biological evaluation. Bioorg Med Chem 2005; 13:2959-66. [PMID: 15781405 DOI: 10.1016/j.bmc.2005.02.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2004] [Revised: 02/03/2005] [Accepted: 02/04/2005] [Indexed: 11/18/2022]
Abstract
Prepared from a commercial prostaglandin building block, novel vitamin D3 analogs with a contracted five-membered A-ring were designed and synthesized to mimic the A-ring diol structure of the natural hormone 1alpha,25-dihydroxyvitamin D3. Prepared from commercial 1,4-cyclohexanedione, a structurally simplified analog was designed and synthesized in which a suitably oriented primary allylic hydroxyl group at the C-2 position might be a surrogate for the biologically important 1alpha-OH in the natural hormone.
Collapse
Affiliation(s)
- Gary H Posner
- Department of Chemistry, The Johns Hopkins University, Baltimore, MD 21218, USA.
| | | | | | | | | | | |
Collapse
|